Meneldor

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Atriva Therapeutics GmbH, founded in 2015 and based in Tübingen, Germany, is a biopharmaceutical company dedicated to developing antiviral therapies for respiratory viral infections, including seasonal and pandemic influenza. The company focuses on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor that targets host cells to inhibit viral replication while also modulating the immune response. Atriva has completed preclinical development for ATR-002 and is seeking guidance from European regulatory authorities to proceed with a Phase I study in healthy volunteers. The company aims to address significant unmet medical needs associated with RNA virus infections, which place a substantial burden on healthcare systems globally.

Atriva Therapeutics GmbH, founded in 2015 and based in Tübingen, Germany, is a biopharmaceutical company dedicated to developing antiviral therapies for respiratory viral infections, including seasonal and pandemic influenza. The company focuses on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor that targets host cells to inhibit viral replication while also modulating the immune response. Atriva has completed preclinical development for ATR-002 and is seeking guidance from European regulatory authorities to proceed with a Phase I study in healthy volunteers. The company aims to address significant unmet medical needs associated with RNA virus infections, which place a substantial burden on healthcare systems globally.

Aptamer Group Limited is a biotechnology company based in York, United Kingdom, specializing in the development of aptamer technologies. Founded in 2008, the company creates nucleic acid aptamers, which are short DNA or RNA sequences that exhibit high affinity and specificity for various targets, serving as alternatives to traditional antibodies. Aptamer Group's offerings span research and development, biomarker discovery, diagnostics, and therapeutics. The company utilizes advanced selection platforms to generate aptamers for a wide range of applications, including imaging, quantification, rapid diagnostics, binding studies, and purification. Their custom services are tailored to optimize aptamers for specific detection platforms and assay conditions. The Aptamer Group is committed to providing innovative solutions that cater to the diverse needs of researchers and developers in the life sciences, leveraging its proprietary Optimer technology across its various business sectors.